Egis Pharmaceuticals's total assets reached HUF 208,238 mil at the end of 2012, up 9.19% compared to the previous year.
Current assets amounted to HUF 125,990 mil, or 60.5% of total assets while cash stood at HUF 45,929 mil at the end of 2012.
By contrast, total debt reached HUF 2,908 mil at the year-end, or 1.40% of total assets, while the firm's equity amounted to HUF 179,490 mil. As a result, net debt stood at HUF -43,021 mil at the end of 2012 and accounted for -0.240 of equity.
Net debt against equity is down 0.173 pp from five years ago (-0.066). The ratio against EBITDA decreased from -0.492x seen in 2007 to -1.41x.
The company’s cost of funding amounted to 1.51% in 2012, down 25.2 pp compared to the average over the last 5 years.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
